Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomized trial.
In a multicenter trial the efficacy of intraperitoneal administration of cisplatin after radical or palliative resection of gastric carcinoma with respect to overall survival was investigated. In 64 randomised patients, patients treated with intraperitoneal perfusion did not show a benefit in the overall survival after a median follow-up of 18 months.